메뉴 건너뛰기




Volumn 9, Issue 6, 2013, Pages 763-775

Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

Author keywords

Canagliflozin; Diabetes mellitus; SGLT2 inhibitor; Sodium glucose cotransporter

Indexed keywords

ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; CANAGLIFLOZIN; DIGOXIN; EMPAGLIFLOZIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INSULIN; INVOKANA; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PARACETAMOL; PHLORIZIN; PIOGLITAZONE; PLACEBO; PROTEIN INHIBITOR; REMOGLIFLOZIN ETABONATE; RIFAMPICIN; SERGLIFLOZIN ETABONATE; SIMVASTATIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; UNCLASSIFIED DRUG; WARFARIN; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

EID: 84877871970     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.791282     Document Type: Review
Times cited : (48)

References (47)
  • 1
    • 38149142887 scopus 로고    scopus 로고
    • world Health Organization, Geneva, Switzerland [Last accessed 17 January 2013]
    • Diabetes fact sheet. world Health Organization, Geneva, Switzerland; 2012. Available from: http://www.who. int/mediacentre/factsheets/fs312/en/index. html [Last accessed 17 January 2013].
    • (2012) Diabetes Fact Sheet
  • 3
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group
    • Turner R, Homan R, Cull A. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53.
    • (1998) Lancet , vol.352 , Issue.9131 , pp. 837-853
    • Turner, R.1    Homan, R.2    Cull, A.3
  • 4
    • 58149389215 scopus 로고    scopus 로고
    • Glucose control and vascular complications in veterans with type 2 diabetes
    • Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39.
    • (2009) N Engl J Med , vol.360 , Issue.2 , pp. 129-139
    • Duckworth, W.1    Abraira, C.2    Moritz, T.3
  • 5
    • 84864270406 scopus 로고    scopus 로고
    • Basal insulin and cardiovascular and other outcomes in dysglycemia
    • Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367(4):319-28.
    • (2012) N Engl J Med , vol.367 , Issue.4 , pp. 319-328
    • Gerstein, H.C.1    Bosch, J.2    Dagenais, G.R.3
  • 6
    • 45149131667 scopus 로고    scopus 로고
    • Effects of intensive glucose lowering in type 2 diabetes
    • Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59.
    • (2008) N Engl J Med , vol.358 , Issue.24 , pp. 2545-2559
    • Gerstein, H.C.1    Miller, M.E.2    Byington, R.P.3
  • 7
    • 45149133036 scopus 로고    scopus 로고
    • Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    • Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24):2560-72.
    • (2008) N Engl J Med , vol.358 , Issue.24 , pp. 2560-2572
    • Patel, A.1    MacMahon, S.2    Chalmers, J.3
  • 8
    • 0042991484 scopus 로고    scopus 로고
    • Implications of the United kingdom prospective diabetes study
    • Genuth S, Eastman R, Kahn R, et al. Implications of the United kingdom prospective diabetes study. Diabetes Care 2003;26(Suppl 1):S28-32.
    • (2003) Diabetes Care , vol.26 , Issue.SUPPL. 1
    • Genuth, S.1    Eastman, R.2    Kahn, R.3
  • 9
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35(6):1364-79.
    • (2012) Diabetes Care , vol.35 , Issue.6 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 10
    • 35348891586 scopus 로고    scopus 로고
    • Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells
    • Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl 2007(106):S27-35.
    • (2007) Kidney Int Suppl , vol.106
    • Lee, Y.J.1    Han, H.J.2
  • 11
    • 75149196250 scopus 로고    scopus 로고
    • Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus
    • Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95(1):34-42.
    • (2010) J Clin Endocrinol Metab , vol.95 , Issue.1 , pp. 34-42
    • Nair, S.1    Wilding, J.P.2
  • 12
    • 4344559467 scopus 로고    scopus 로고
    • The glucose transporter families SGLT and GLUT: Molecular basis of normal and aberrant function
    • Scheepers A, Joost HG, Schurmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 2004;28(5):364-71.
    • (2004) JPEN J Parenter Enteral Nutr , vol.28 , Issue.5 , pp. 364-371
    • Scheepers, A.1    Joost, H.G.2    Schurmann, A.3
  • 13
    • 0033870323 scopus 로고    scopus 로고
    • T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats
    • Adachi T, Yasuda K, Okamoto Y, et al. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism 2000;49(8):990-5.
    • (2000) Metabolism , vol.49 , Issue.8 , pp. 990-995
    • Adachi, T.1    Yasuda, K.2    Okamoto, Y.3
  • 14
    • 48249146624 scopus 로고    scopus 로고
    • Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
    • Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57(6):1723-9.
    • (2008) Diabetes , vol.57 , Issue.6 , pp. 1723-1729
    • Han, S.1    Hagan, D.L.2    Taylor, J.R.3
  • 15
    • 33845873376 scopus 로고    scopus 로고
    • Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level
    • Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007;320(1):323-30.
    • (2007) J Pharmacol Exp Ther , vol.320 , Issue.1 , pp. 323-330
    • Katsuno, K.1    Fujimori, Y.2    Takemura, Y.3
  • 16
    • 84857099986 scopus 로고    scopus 로고
    • Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models
    • Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012;7:e30555.
    • (2012) PLoS One , vol.7
    • Liang, Y.1    Arakawa, K.2    Ueta, K.3
  • 17
    • 77956319973 scopus 로고    scopus 로고
    • Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus
    • Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010;53(17):6355-60.
    • (2010) J Med Chem , vol.53 , Issue.17 , pp. 6355-6360
    • Nomura, S.1    Sakamaki, S.2    Hongu, M.3
  • 19
    • 0023275573 scopus 로고
    • Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats
    • Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79(5):1510-15.
    • (1987) J Clin Invest , vol.79 , Issue.5 , pp. 1510-1515
    • Rossetti, L.1    Smith, D.2    Shulman, G.I.3
  • 20
    • 84877867249 scopus 로고    scopus 로고
    • Advisory committee briefing materials: Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus
    • Janssen Research & Development LLC. Advisory committee briefing materials: Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. Endocrinologic and Metabolic Drugs Advisory Committee 2012. p. 1-184.
    • (2012) Endocrinologic and Metabolic Drugs Advisory Committee , pp. 1-184
    • Research, J.1    Llc, D.2
  • 21
    • 84877847032 scopus 로고    scopus 로고
    • National Center For Biotechnology Information; U.S. National Library Of Medicine Bethesda MD Last Accessed 21 March 2013
    • Canagliflozin - compound summary. National Center for Biotechnology Information; U.S. National Library of Medicine, Bethesda, MD; 2008. Available from: http://pubchem. ncbi.nlm.nih.gov/summary/summary.cgicid=24812758 [Last accessed 21 March 2013].
    • (2008) Canagliflozin - Compound Summary
  • 22
    • 83655184724 scopus 로고    scopus 로고
    • Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT- 2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors
    • Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT- 2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14(1):83-90.
    • (2012) Diabetes Obes Metab , vol.14 , Issue.1 , pp. 83-90
    • Grempler, R.1    Thomas, L.2    Eckhardt, M.3
  • 23
    • 84860252876 scopus 로고    scopus 로고
    • Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
    • Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14(6):539-45.
    • (2012) Diabetes Obes Metab , vol.14 , Issue.6 , pp. 539-545
    • Devineni, D.1    Morrow, L.2    Hompesch, M.3
  • 24
    • 84877865378 scopus 로고    scopus 로고
    • Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: Results of a randomized placebo-controlled study
    • Published Online 14 February 2013; doi: 10.2337/dc12-2391
    • Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013; published online 14 February 2013; doi: 10.2337/dc12-2391.
    • (2013) Diabetes Care
    • Polidori, D.1    Sha, S.2    Mudaliar, S.3
  • 25
    • 79956331954 scopus 로고    scopus 로고
    • Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
    • Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13(7):669-72.
    • (2011) Diabetes Obes Metab , vol.13 , Issue.7 , pp. 669-672
    • Sha, S.1    Devineni, D.2    Ghosh, A.3
  • 26
    • 80052890663 scopus 로고    scopus 로고
    • Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (sglt2), increases 24-h urinary glucose excretion and decreases body weight in obese subjects [abstract]
    • [Last accessed 17 January 2013]
    • Sarich T, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (sglt2), increases 24-h urinary glucose excretion and decreases body weight in obese subjects [abstract]. Diabetes 2010;59(Suppl 1). Available from: http://professional.diabetes.org/Abstracts- Display.aspxTYP=1&CID=79515 [Last accessed 17 January 2013].
    • (2010) Diabetes , vol.59 , Issue.SUPPL. 1
    • Sarich, T.1    Devineni, D.2    Ghosh, A.3
  • 27
    • 79952984824 scopus 로고    scopus 로고
    • Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes and was well tolerated [abstract]
    • [Last accessed 17 January 2013]
    • Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes and was well tolerated [abstract]. Diabetes 2010;59(Suppl 1). Available from: http://professional.diabetes.org/Abstracts-Display.aspxTYP= 1&CID=79516 [Last accessed 17 January 2013].
    • (2010) Diabetes , vol.59 , Issue.SUPPL. 1
    • Sha, S.1    Devineni, D.2    Ghosh, A.3
  • 28
    • 0015122757 scopus 로고
    • Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects
    • Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971;28(1):101-9.
    • (1971) Scand J Clin Lab Invest , vol.28 , Issue.1 , pp. 101-109
    • Mogensen, C.E.1
  • 29
    • 33748064644 scopus 로고    scopus 로고
    • Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes-results of a hyperglycaemic glucose clamp study
    • Rave K, Nosek L, Posner J, et al. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes-results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant 2006;21(8):2166-71.
    • (2006) Nephrol Dial Transplant , vol.21 , Issue.8 , pp. 2166-2171
    • Rave, K.1    Nosek, L.2    Posner, J.3
  • 30
    • 80052084915 scopus 로고    scopus 로고
    • Canagliflozin treatment improves beta cell function in subjects with type 2 diabetes [abstract]
    • [Last accessed 17 January 2013]
    • Polidori D, Zhao Y, Sha S, Canovatchel W. Canagliflozin treatment improves beta cell function in subjects with type 2 diabetes [abstract]. Diabetes 2010;59(Suppl 1). Available from: http://professional.diabetes.org/ Abstracts-Display.aspxTYP=1&CID=79592 [Last accessed 17 January 2013].
    • (2010) Diabetes , vol.59 , Issue.SUPPL. 1
    • Polidori, D.1    Zhao, Y.2    Sha, S.3    Canovatchel, W.4
  • 31
    • 84877844057 scopus 로고    scopus 로고
    • Lack of clinically meaningful interaction between canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, and digoxin or warfarin in healthy subjects [abstract]
    • Devineni D, Manitpisitkul P, Vaccaro N, et al. Lack of clinically meaningful interaction between canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, and digoxin or warfarin in healthy subjects [abstract]. Clin Pharmacol Drug Dev 2012;1:81.
    • (2012) Clin Pharmacol Drug Dev , vol.1 , pp. 81
    • Devineni, D.1    Manitpisitkul, P.2    Vaccaro, N.3
  • 32
    • 80052813670 scopus 로고    scopus 로고
    • The effects of multiple doses of canagliflozin on the pharmacokinetics and safety of single doses of an oral contraceptive containing ethinyl estradiol and levonorgestrel [abstract]
    • Skee D, Shalayda K, Vandebosch A, et al. The effects of multiple doses of canagliflozin on the pharmacokinetics and safety of single doses of an oral contraceptive containing ethinyl estradiol and levonorgestrel [abstract]. Clin Pharmacol Ther 2010;87(Suppl 1):S35.
    • (2010) Clin Pharmacol Ther , vol.87 , Issue.SUPPL. 1
    • Skee, D.1    Shalayda, K.2    Vandebosch, A.3
  • 33
    • 85058631060 scopus 로고    scopus 로고
    • Effects of Canagliflozin on the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Metformin and Glyburide [abstract]
    • San Diego CA
    • Devineni D, Sarich TC, Wexler D, et al. Effects of canagliflozin on the pharmacokinetics (PK) and pharmacodynamics (PD) of metformin and glyburide [abstract]. American Diabetes Association 71st Scientific Sessions. San Diego, CA; 2011.
    • (2011) American Diabetes Association 71st Scientific Sessions
    • Devineni, D.1    Sarich, T.C.2    Wexler, D.3
  • 34
    • 84874291673 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
    • Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 372-382
    • Stenlof, K.1    Cefalu, W.T.2    Kim, K.A.3
  • 35
    • 84861781220 scopus 로고    scopus 로고
    • Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes
    • Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35(6):1232-8.
    • (2012) Diabetes Care , vol.35 , Issue.6 , pp. 1232-1238
    • Rosenstock, J.1    Aggarwal, N.2    Polidori, D.3
  • 36
    • 84880005461 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin a sodium glucose co-transporter 2 inhibitor compared with glimepiride in patients with type 2 diabetes on background metformin [abstract]
    • Philadelphia PA
    • Cefalu WT, Leiter LA, Niskanen L, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin [abstract]. American Diabetes Association 72nd Scientific Sessions. Philadelphia, PA; 2012.
    • (2012) American Diabetes Association 72nd Scientific Sessions
    • Cefalu, W.T.1    Leiter, L.A.2    Niskanen, L.3
  • 38
    • 84875168195 scopus 로고    scopus 로고
    • Canagliflozin (CANA) A Sodium Glucose Co-transporter 2 Inhibitor Improves Glycemic Control and Reduces Body Weight in Subjects with Type 2 Diabetes (T2D) Inadequately Controlled with Metformin (MET) and Sulfonylurea (SU) [abstract]
    • Philadelphia PA
    • Wilding JP, Mathieu C, Vercruysse F, et al. Canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes (T2D) inadequately controlled with metformin (MET) and sulfonylurea (SU) [abstract]. American Diabetes Association 72nd Scientific Sessions. Philadelphia, PA; 2012.
    • (2012) American Diabetes Association 72nd Scientific Sessions
    • Wilding, J.P.1    Mathieu, C.2    Vercruysse, F.3
  • 39
    • 84885360883 scopus 로고    scopus 로고
    • Efficacy and Safety of Canagliflozin A Sodium Glucose Co-transporter 2 Inhibitor Compared with Sitagliptin in Patients with Type 2 Diabetes on Metformin Plus Sulfonylurea [abstract]
    • Philadelphia PA
    • Gross J, Schernthaner G, Fu M, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with sitagliptin in patients with type 2 diabetes on metformin plus sulfonylurea [abstract]. American Diabetes Association 72nd Scientific Sessions. Philadelphia, PA; 2012.
    • (2012) American Diabetes Association 72nd Scientific Sessions
    • Gross, J.1    Schernthaner, G.2    Fu, M.3
  • 40
    • 84877855570 scopus 로고    scopus 로고
    • Efficacy and Safety of Canagliflozin (CANA) An Inhibitor of Sodium Glucose Co-transporter 2 (SGLT2) Added-on to Insulin Therapy +- Oral Agents in Type 2 Diabetes [abstract]
    • Berlin Germany
    • Matthews DR, Fulcher G, Perkovic V, et al. Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/- oral agents in type 2 diabetes [abstract]. 48th European Association for the Study of Diabetes Annual Meeting. Berlin, Germany; 2012.
    • (2012) 48th European Association for the Study of Diabetes Annual Meeting
    • Matthews, D.R.1    Fulcher, G.2    Perkovic, V.3
  • 41
    • 84877866941 scopus 로고    scopus 로고
    • Efficacy and Safety of Canagliflozin (CANA) A Sodium Glucose Co-transporter 2 Inhibitor (SGLT2) in Older Subjects with Type 2 Diabetes Mellitus [abstract]
    • Berlin Germany
    • Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor (SGLT2), in older subjects with type 2 diabetes mellitus [abstract]. 48th European Association for the Study of Diabetes Annual Meeting. Berlin, Germany; 2012.
    • (2012) 48th European Association for the Study of Diabetes Annual Meeting
    • Bode, B.1    Stenlof, K.2    Sullivan, D.3
  • 42
    • 84876311251 scopus 로고    scopus 로고
    • Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes and Chronic Kidney Disease
    • Published Online 06 Mar 2013; doi: 10.1111/dom.12090
    • Yale J-F, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; published online 06 Mar 2013; doi: 10.1111/dom.12090.
    • (2013) Diabetes Obes Metab
    • Yale, J.-F.1    Bakris, G.2    Cariou, B.3
  • 43
    • 84863617006 scopus 로고    scopus 로고
    • Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor
    • Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012;28(7):1173-8.
    • (2012) Curr Med Res Opin , vol.28 , Issue.7 , pp. 1173-1178
    • Nyirjesy, P.1    Zhao, Y.2    Ways, K.3    Usiskin, K.4
  • 44
    • 84877845736 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration, Silver Spring, Maryland [Last accessed 17 January 2013]
    • Endocrinologic and metabolic drugs advisory committee meeting announcement. U.S. Food and Drug Administration, Silver Spring, Maryland; 2013. Available from: http://www.fda. gov/AdvisoryCommittees/Calendar/ucm331503.htm [Last accessed 17 January 2013].
    • (2013) Endocrinologic and Metabolic Drugs Advisory Committee Meeting Announcement
  • 46
    • 84869998632 scopus 로고    scopus 로고
    • Dapagliflozin: A review of its use in type 2 diabetes mellitus
    • Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012;72(17):2289-312.
    • (2012) Drugs , vol.72 , Issue.17 , pp. 2289-2312
    • Plosker, G.L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.